drugset / Trial / NCT00345540
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
Phase 2
Completed
15 enrolled
Cellectar Biosciences, Inc.
Dana-Farber Cancer Institute · collabMassachusetts General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.
Timeline
- Start
- 2006-07
- Primary completion
- 2008-05
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NOV-002 | Unknown | 60 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |